Abstract TU254: Global Impact of Tobacco Control Policies on Cardiovascular Mortality: A Lag-Adjusted Fixed-Effects Analysis of 148 Countries (2007–2022)

A Anusha Parisapogu (University of Connecticut, Hartford , India) H Hardik Dineshbhai Desai A Asmita Gera (Maimonides medical Center,, Brooklyn, New York, United States) S SHAHZAD AHMED SAMI (DCH RMC/university of Alabama ,, Tuscaloosa, Alabama, United States) F FNU Parul (U of M Health- Sparrow Hospital, Lansing, Michigan, United States) M Manas Gunani (Allegheny Health Network, Pittsburgh, Pennsylvania, United States) S Siri Vummaneni (Detroit Medical Center/Wayne State University. 4201 St. Antoine St Detroit,, Detroit, Michigan, United States) R Revati Varma (Department of Cardiovascular Medicine (Y.N.V.R., R.P.F., W.R.M., R.V., B.A.B.), Mayo Clinic, Rochester, MN.) S Sourav Sudan (St Vincent Hospital,, Worcester, Massachusetts, United States) N Naga Teja Yedida (Rangaraya Medical College,, Kakinada, Andhra Pradesh, India)

Abstract

Background: Tobacco use remains a leading modifiable driver of cardiovascular disease (CVD) worldwide. The WHO MPOWER framework quantifies national tobacco-control strength, yet longitudinal causal associations with CVD mortality have not been comprehensively quantified across countries. Methods: A longitudinal panel of 148 countries (2007–2022) was assembled integrating: (1) Global Burden of Disease 2023 estimates of age-standardized CVD mortality attributable to tobacco (per 100 000); (2) WHO MPOWER composite scores (0–5 scale, equal-weighted across six policy components); and (3) World Bank GDP per capita (USD). We applied country- and year-fixed-effects linear regression to estimate the association between MPOWER intensity at t–3 and subsequent CVD mortality at year t , adjusting for log-transformed GDP. The three-year lag was selected a priori , consistent with cardiovascular disease latency periods. Robust (HC3) standard errors were clustered by country. Sensitivity analyses tested alternate lag structures (t–1 to t–5), exclusion of outliers (±3 SD or high Cook’s distance), and GDP-by-income-level interaction terms. Results: From 2007–2022, global tobacco-attributable CVD mortality declined from 37.3 to 32.4 per 100 000 (–13.2%), as mean MPOWER strength increased from 2.7 to 2.9. Each one-point increase in lagged MPOWER score was associated with a 1.07 ± 0.20 per 100 000 reduction in CVD mortality ( p < 0.001), independent of GDP ( β = –2.10 ± 0.69; p = 0.002). Over the full MPOWER scale (0→5), this translates to ~5.4 fewer deaths per 100 000, representing a 16% decline at mean baseline mortality. A 1% increase in GDP corresponded to a 0.021 per 100 000 reduction in CVD mortality. Model fit was strong (within-country R 2 = 0.71; total R 2 = 0.97). Income-level interactions were non-significant, indicating consistent MPOWER effects across development contexts. High-policy countries (UK, Australia, Japan, Brazil) achieved steepest declines, while lower-policy countries (Nigeria, Ethiopia, Pakistan) showed limited progress. Conclusions: Stronger MPOWER implementation, sustained over multiple years, is independently associated with substantial reductions in tobacco-attributable CVD mortality worldwide, even after accounting for GDP, year effects, and lag structure. While residual confounding and ecological inference limit causal certainty, these findings provide robust, policy-relevant evidence supporting global intensification of comprehensive tobacco control.

Article Details

Journal Circulation
Volume / Issue Vol. 153, Issue Suppl_1
Published March 24, 2026
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (10)

A

Anusha Parisapogu

University of Connecticut, Hartford , India

H

Hardik Dineshbhai Desai

A

Asmita Gera

Maimonides medical Center,, Brooklyn, New York, United States

S

SHAHZAD AHMED SAMI

DCH RMC/university of Alabama ,, Tuscaloosa, Alabama, United States

F

FNU Parul

U of M Health- Sparrow Hospital, Lansing, Michigan, United States

M

Manas Gunani

Allegheny Health Network, Pittsburgh, Pennsylvania, United States

S

Siri Vummaneni

Detroit Medical Center/Wayne State University. 4201 St. Antoine St Detroit,, Detroit, Michigan, United States

R

Revati Varma

Department of Cardiovascular Medicine (Y.N.V.R., R.P.F., W.R.M., R.V., B.A.B.), Mayo Clinic, Rochester, MN.

S

Sourav Sudan

St Vincent Hospital,, Worcester, Massachusetts, United States

N

Naga Teja Yedida

Rangaraya Medical College,, Kakinada, Andhra Pradesh, India